Covidien

Covidien
Share
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes, and services a diverse range of industry-leading product lines. Stop by our booth to learn more about our products.

Covidien

 •  January 22, 2015

DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 22, 2015-- Covidien plc (NYSE: COV) today announced financial results for the first quarter of fiscal 2015. First-quarter net sales of $2.69 billion increased 2% from the $2.64 billion in the first quarter a year ago. Operational sales growth in the quarter was 6%, as foreign exchange rate movement lowered ...

Covidien

 •  January 21, 2015

DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 21, 2015-- In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on January 20, 2015, the Company’s issued share capital, excluding treasury shares, consisted of 454,507,245 ordinary shares, par value US$0.20 per share ...

Covidien

 •  January 15, 2015

DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 15, 2015-- Covidien plc (NYSE: COV) will report first-quarter fiscal 2015 results on January 22. Results will be filed via Form 8K and available prior to market open at www.covidien.com/investor. The company will not be hosting a conference call.About Covidien Covidien is a global health care leader that ...

Covidien

 •  January 14, 2015

DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 14, 2015-- In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on January 13, 2015, the Company’s issued share capital, excluding treasury shares, consisted of 454,294,351 ordinary shares, par value US$0.20 per share ...

Covidien

 •  January 8, 2015

Stellarex™ DCB featuring EnduraCoat™ technology designed to restore blood flow and prevent formation of new blockages
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 8, 2015-- Covidien plc (NYSE:COV) today announced it has received CE Mark approval for its Stellarex™ drug-coated angioplasty balloon (DCB). The Stellarex™ DCB is used to restore and maintain ...

Covidien

 •  January 8, 2015

DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 8, 2015-- In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on January 7, 2015, the Company’s issued share capital, excluding treasury shares, consisted of 454,109,105 ordinary shares, par value US$0.20 per share (the ...

Covidien

 •  December 30, 2014

DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 30, 2014-- In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 29, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 454,006,720 ordinary shares, par value US$0.20 per share ...

Covidien

 •  December 23, 2014

DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 23, 2014-- In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 22, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 453,883,765 ordinary shares, par value US$0.20 per share ...

Covidien

 •  December 17, 2014

Innovative design of wireless, vitamin-sized capsule recognized for its profound impact on improving the standard-of-care for small bowel examinations
NEW YORK--(BUSINESS WIRE)--Dec. 17, 2014-- PillCam® SB, Covidien’s wireless capsule endoscope, is now featured in the exhibit, “Tools: Extending Our Reach” at New York’s Cooper Hewitt Smithsonian ...

Covidien

 •  December 17, 2014

DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 17, 2014-- In a landmark study evaluating the addition of stent thrombectomy clot removal to pharmaceutical treatment for patients suffering an acute ischemic stroke (AIS), stent thrombectomy provided a significant clinical benefit when compared to pharmaceutical treatment alone. Results from the Multi center ...